News & Publications

NEWS & PUBLICATIONS

Learn more about Prous Institute and our progress in drug discovery, technology, industry partnerships, collaborations and scientific articles.

Nomination Call for the 2016 Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery

2015 Oct 20 |
Category: News, Technology

Barcelona. Prous Institute for Biomedical Research is proud to announce the nomination call for the 2016 Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery. Following their tradition of drug discovery science and technology, Prous Institute has donated the award biennially since 2004, acknowledging outstanding achievements in the field of medicinal chemistry. Next year’s award will be given at the XXIV EFMC “International Symposium on Medicinal Chemistry” (EFMC-ISMC) to be held in Manchester, UK from August 28 to September 1, 2016. The deadline for nominations is January 31, 2016.

About the Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery

The award was established to encourage innovation and investigation in technologies related to drug discovery. It consists of a monetary prize, a diploma, and an invitation to give a lecture at the upcoming EFMC-ISMC International Symposium on Medicinal Chemistry.

The requirements for a nomination for the Prous Institute-Overton and Meyer Award, are: a nomination letter, a brief CV including a list of selected publications and two supporting letters. Self-nominations are also accepted. The nominations should be submitted to Prof. Koen Augustyns, President of the EFMC, via this link. More information is available here.

About Prous Institute for Biomedical Research

Prous Institute for Biomedical Research is a privately-held research organization created in order to put into practice innovative in silico approaches to accelerate drug discovery. It was founded as a spin-off of Prous Science, the leading scientific information provider (creator of brands such as Integrity, MDDR, Drugs of the Future, Drug Data Report, Drugs of Today, Drug News and Perspectives, Methods and Findings in Experimental and Clinical Pharmacology and Timely Topics in Medicine) acquired by Thomson Reuters in 2007. Building on over 50 years of experience creating and managing biomedical knowledge, Prous Institute for Biomedical Research has developed Symmetry, an innovative predictive analytics platform to elucidate the efficacy and safety profile of new molecular entities. The platform helps to de-risk and prioritize projects and assays and speed up drug discovery and development, reducing time, costs and attrition rates. Symmetry applies advanced machine learning techniques to a variety of structural features and physicochemical properties of small molecules to provide quality predictions of biological effects.

For more information, please contact Prous Institute.